ETF name(Code), Benchmark Index, Inception date, creation unit, Net Asset (KRW 0.1 billion), Trustee, Rule of Dividend payment, Market Price per share (KRW), iNAV per share (KRW), trading volume (share), Total Expense ratio table
ETF Name (code)
Benchmark Index
Inception date
Creation Unit
AUM (KRW)
KB RISE HealthCare Fixed Income Balanced ETF
(253290)
FnGuide HealthCare Mix Index
2016.09.23
200,000
15,398,234,932
Trustee
Market Price per share (KRW)
NAV
Trading Volume (shares)
하나은행
12,760
※ t-1 last price
12,831
40,350
authorized participant, Liquidity provider table
Total Expense Ratio
Distribution Frequency
Year 0.35%
(Designated participating company : 0.001%,
Collective investment : 0.309%,
trust : 0.02%,
General affairs : 0.02%)
Based on the business day before the interest payment date of the stocks constituting the index in June and December (occasional payment)
The FnGuide Healthcare Balanced Index is an index consisting of stock items constituting the FnGuide Healthcare Index and three KTBs constituting the MKF 3-year KTB Index. It maintains a 7:3 ratio of bonds to stocks everyday.
Name, Ticker, Number. of shares, Weight(%), market price (KRW)
No. (Number)
Name
Ticker
Number of shares
Weight(%)
Market price (KRW)
1
KTB02625-3003(25-3)
KR103503GF38
666,666,666
25.28
654,713,999
2
KTB02875-2712(24-12)
KR103501GEC6
500,000,000
19.56
506,468,500
3
RISE HealthCare
KR7253280002
20,641
13.87
359,153,400
4
RISE KTB
KR7114100001
1,900
7.96
206,254,500
5
KTB02250-2806(25-4)
KR103501GF63
166,666,666
6.39
165,385,499
6
원화예금
KRD010010001
122,359,750
4.72
122,359,750
7
F 202512
KR4165WC0006
0.67
2.71
70,306,596
8
Alteogen
KR7196170005
117
2.34
60,723,000
9
Celltrion
KR7068270008
294
2.07
53,684,400
10
SAMSUNG BIOLOGICS
KR7207940008
30
1.95
50,400,000
11
ABL Bio
KR7298380007
237
1.84
47,637,000
12
Yuhan
KR7000100008
392
1.79
46,412,800
13
HLB
KR7028300002
822
1.53
39,702,600
14
LCB
KR7141080002
184
1.39
36,082,400
15
SKBP
KR7326030004
192
1.01
26,169,600
16
SCD
KR7000250001
98
0.85
21,903,000
17
PharmaResearch
KR7214450009
48
0.76
19,728,000
18
HanmiPharm
KR7128940004
44
0.73
18,920,000
19
HANALL BIOPHARMA
KR7009420001
248
0.54
13,888,000
20
ST Pharm
KR7237690003
88
0.4
10,375,200
21
SKBS
KR7302440003
186
0.39
10,118,400
22
SAMSUNG EPIS HOLDINGS
KR70126Z0002
16
0.34
8,912,000
23
Celltrionph
KR7068760008
141
0.34
8,756,100
24
Hugel
KR7145020004
37
0.32
8,177,000
25
L&C BIO
KR7290650001
117
0.3
7,663,500
26
CLASSYS
KR7214150005
123
0.26
6,777,300
27
Pharmicell
KR7005690003
393
0.26
6,704,580
28
CHA Biotech
KR7085660009
375
0.23
5,865,000
29
SEEGENE
KR7096530001
225
0.22
5,771,250
30
DAEWOONG PHARM
KR7069620003
32
0.22
5,766,400
31
GC Corp
KR7006280002
39
0.21
5,350,800
32
Hanmi Science
KR7008930000
143
0.2
5,305,300
33
HK inno.N
KR7195940002
100
0.2
5,260,000
34
MedyTox
KR7086900008
38
0.19
4,810,800
35
ShinpoongPharm
KR7019170000
232
0.13
3,391,840
36
HLBPHARMA
KR7047920004
196
0.12
3,055,640
37
DongKook Pharm
KR7086450004
165
0.12
3,118,500
38
Binex
KR7053030003
202
0.11
2,902,740
39
CUREXO
KR7060280005
204
0.11
2,856,000
40
EuBio
KR7206650004
219
0.1
2,717,790
41
DENTIUM
KR7145720009
46
0.09
2,359,800
42
SD Biosensor
KR7137310009
245
0.09
2,285,850
43
BIONEER
KR7064550007
156
0.09
2,226,120
44
WONTECH
KR7336570007
302
0.09
2,231,780
45
Huons Global
KR7084110006
38
0.08
2,059,600
46
SELVAS AI
KR7108860008
166
0.08
2,149,700
47
BioPlus
KR7099430001
291
0.06
1,606,320
48
T&L
KR7340570001
32
0.06
1,606,400
Investment notice
- The information provided on this website is based on reliable sources, but its accuracy and completeness are not guaranteed.
- Financial investment products are not protected by the Korea Deposit Insurance Corporation in accordance with the Depositor Protection Act, and a loss of investment principal may occur, which belongs to the investor.
- Past performance does not guarantee future profits.
- In the case of a collective investment scheme that invests in foreign securities, asset values may be lost due to risks caused by market, political, and economic conditions in the target country.
- Derivatives may lose all or a significant portion of the investment principal in a short period of time due to high price volatility, and there is a risk that the counterparty may not be able to fulfill the terms of the contract when investing in over-the-counter derivatives.
- Before investing, be sure to read the investment prospectus and contract recommendation document regarding the investment subject, redemption method, and fee.
There are no products in the comparison box. Please include products to compare!